U.S. Completed OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematological Malignancies Hematological ...

The ACCESS trial is a multicenter, phase 2 trial designed to compare overall survival in patients receiving mismatched unrelated donor peripheral blood stem cells as an allograft source for ...

Furthermore, the research team conducted a single-center peripheral blood stem cell transplantation cohort study as well as a multicenter haploidentical transplantation validation cohort study in ...

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a critical therapeutic strategy for treating conditions such as hematological ...

Research has shown that autologous hematopoietic stem cell transplantation is an effective treatment for MS. At 2 years and 4 years post-transplant, relapse-free survival rates were 94% and 89% ...

Peripheral neural stem cells have the same cell morphology, self-renewal and differentiation capacity as neural stem cells of the brain. They express several specific markers and have genome-wide ...

Researchers analyzed gene expression and chromatin accessibility to detect populations with stem cell–like properties ... location of these cells in the peripheral retina.

Restoring those stem cells by growing them in a lab can treat the cell deficiency that gives rise to corneal blood vessel growth, cloudiness and pain, Jurkunas said. Jurkunas said the transplant ...